Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome (PCOS) affects 5%-10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins. Rescuing the ovarian response to endogenous gonadotropins reduces hyperandrogenemia and re-establishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy. Among the insulin-sensitizing compounds, there is myo-inosiol (MYO). Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. With the present review, we aim to provide an overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS.
Symptoms include: Irregular or irregular menstruation, Menorrhagia, Hirsutism, Acne, Pelvic Pain, Difficult to conceive, Acanthosis nigricans
Scientist Home Mixed Inositol
Possible supplements supporting::
- Periodic discomfort(1,2,3)
- Thinning hair(4)
- Labial hair(5)
- Body hair(5)
- Sleep disturbances(7)
1. Gerli S, Papaleo E, Ferrari A, et al. Randomized, double-blind, placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347-354
2. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary
syndrome: a double-blind trial. Eur Rev. Med Pharmacol Sci. 2009;13(2):105-110.
3. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275-280.
4. Ablon Glynis, MD, FAAD. A Double-blind, Placebo-controlled Study Evaluating the Efficacy of an Oral Supplement in Women with Self-perceived Thinning Hair. J Clin Aesthet Dermatol. v.5(11); 2012 Nov. PMC3509882
5. M Minozzi,1 G D’Andrea,2 V Unfer2,31First Institute of Obstetrics and Gynecology, University La Sapienza; 2A.G.UN.CO. Obstetrics and Gynecology Centre, Rome, Italy. Treatment of hirsutism with myo-inositol: a prospective clinical study. RBMOnline - Vol 17 No 4. 2008 579-582 Reproductive BioMedicine Online; www.rbmonline.com/Article/3299 on web 20 August 2008.
6. Michele Pezza, Valentina Carlomagno, Ambulatorio di Dermatologia Casa di Cura Villa Maria Passo di Mirabella Eclano (AV), Italy. Inositol in women suffering from acne and PCOS: a randomized study . DOI: 10.15761/GOD.10002037. Renae C Fernandez,1,2,3 Vivienne M. Moore,1,3,4 Emer M Van Ryswyk,5 Tamara J Varcoe,1,2 Raymond J Rodgers,1,2 Wendy. A March,1,3 Lisa J Moran,1,6 Jodie C Avery,1,2 R Doug McEvoy,5,7 and Michael J. Davies1,2. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Journal List Nat Sci Sleep v.10; 2018 PMC5799701
8. Michele Pezza, Valentina Carlomagno. Inositol in women suffering from acne and PCOS: a randomized study. DOI: 10.15761/GOD.1000203